Experienced in the field of monoclonal antibody development for decades of years, Creative Biolabs has established a high-throughput B cell sorting platform for the screening of a large number of B-cells from various hosts to develop antibodies.
Monoclonal antibody (mAb) has experienced the iterative update from mouse mAb, chimeric antibody, and humanized antibody to whole human antibody since the emergence of hybridoma technology in 1975. The overall trend is to increase the humanization of antibodies due to the rapid human anti-mouse immune reaction in the human body. This species’ immune reaction not only accelerates the clearance of murine antibodies leading to a decreased titer but also causes adverse allergic reactions. At present, mature antibody production technologies, including hybridoma technology, phage display technology, and transgenic mouse technology, show different limitations, such as inevitable immunogenicity, low affinity, cost, and time consumption, the most important of which is that they cannot provide antibodies with naturally paired heavy chain and light chain.
To overcome the limitations of current antibody technologies, single B cell sorting antibody technology has been developed and thrived which allows us to efficiently produce the desired antibody in a time-saving manner. Moreover, this new technology can retrieve Native™ antibodies with extremely high in vivo specificity and affinity, as well as the pairing of VH and VL.
Fig.1 Workflow of B cell mAb discovery pipeline.1, 3
During the Native™ antibody development, the isolation and identification of single antibody-secreting B (ASB) cells are important and are the main technically challenging tasks. The yield and quality or in other words the integrity and purity of the cells, as well as the throughput and the sensitivity of single-cell isolation methods, should be considered. Firstly and importantly, to isolate target antigen-specific ASB cells, it needs to label antigen instead of B cells, by which the labeled antigen can recognize and bind to the surface of the target ASB cells. Then specific target B cells are isolated by a variety of sorting methods and technologies, which mainly including but not limited to:
Fig.2 Overview of single-cell isolation technologies.2, 3
Creative Biolabs, a reputable CRO service provider focusing on therapeutic antibody discovery, has accumulated profound expertise and extensive experience in antibody development. To better serve our valued customers, we integrate technological resources and set up a special B cell sorting platform. Our knowledgeable scientist team provides a broad spectrum of Native™ antibody discovery services and related products, covering:
Please feel free to contact us and our experienced technicians will give you the most detailed answers to your questions.
References
